Bedside NT-proBNP Monitoring in Acute Heart Failure
Trial statusNot yet recruiting
Trial phaseNot listed
Trial typeObservational
Biological sexAll
Age18+
SponsorMao Chen
About this trial
The goal of this observational study is to investigate the association between dynamic changes in NT-proBNP levels and clinical decongestion status in patients with acute decompensated heart failure (ADHF) receiving guideline-directed standard medical treatment.
The main question it aims to answer is:
Among patients with acute decompensated heart failure treated according to current clinical guidelines, are changes in NT-proBNP levels during hospitalization associated with successful clinical decongestion?
Participants will receive standard-of-care treatment for ADHF according to treating physicians' clinical decisions and current guideline recommendations. During hospitalization, serial NT-proBNP measurements and repeated assessments of congestion status will be performed to evaluate the relationship between NT-proBNP dynamics and the process of decongestion.
This study is purely observational and will not assign treatments or modify clinical management. The findings may improve understanding of the role of NT-proBNP dynamics as a marker of treatment response and provide preliminary evidence for future studies on individualized management of acute heart failure.
Eligibility criteria
Qualifiers
Adults aged ≥18 years.
Patients hospitalized in the cardiac intensive care unit (CCU) with a diagnosis of acute decompensated heart failure (ADHF).
Symptoms or signs of volume overload (e.g., dyspnea, orthopnea, peripheral edema, elevated jugular venous pressure).
Pulmonary congestion based on physical examination or imaging findings.
Disqualifiers
Cardiogenic shock or requirement for immediate mechanical circulatory support.
End-stage kidney disease requiring maintenance dialysis or renal replacement therapy at admission.
Acute conditions requiring urgent intervention that may interfere with study assessments, including acute coronary syndrome requiring immediate revascularization or acute pulmonary embolism.
Clinical conditions in which NT-proBNP interpretation is considered unreliable or inappropriate by the investigator.
Trial design
Treatments tested in this trial
- Serial NT-proBNP Measurement
Treatment groups
50 Participants
are divided into 1 treatment groupLocations
Sponsors and collaborators
Mao Chen
Lead sponsor
West China Hospital
Sponsor institution
Source ClinicalTrials.gov